Lung and Lobar Lung Transplant

**Policy Number:** 7.03.07  
**Last Review:** 11/2016  
**Origination:** 11/2001  
**Next Review:** 11/2017

**Policy**
Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for lung and lobar lung transplant when it is determined to be medically necessary because the criteria shown below are met.

**When Policy Topic is covered**
Lung transplantation may be considered **medically necessary** for carefully selected patients with irreversible, progressively disabling, end-stage pulmonary disease unresponsive to maximum medical therapy, including but not limited to one of the conditions listed below.

A lobar lung transplant from a living or cadaver donor may be considered **medically necessary** for carefully selected patients with end-stage pulmonary disease including but not limited to one of the conditions listed below.

<table>
<thead>
<tr>
<th>CODES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-1 antitrypsin deficiency</td>
</tr>
</tbody>
</table>
| Bilateral bronchiectasis | 494.0 – 494.1  
748.61 for congenital bronchiectasis |
| Bronchiolitis obliterans | 491.8 |
| Bronchopulmonary dysplasia | 770.7 |
| Chronic obstructive pulmonary disease | 496 |
| Cystic fibrosis (both lungs to be transplanted) | 277.00 – 277.09 |
| Eisenmenger’s syndrome | 745.4 |
| Emphysema | 492.8 |
| Eosinophilic granuloma | 277.89 |
| Idiopathic/Interstitial pulmonary fibrosis | 516.3 |
| Postinflammatory pulmonary fibrosis | 515 |
| Lymphangiomyomatosis | 516.4 |
| Primary pulmonary hypertension | 416.0 |
| Pulmonary hypertension due to cardiac disease | 416.8 |
| Recurrent pulmonary embolism | 415.11 – 415.19 |
| Sarcoidosis | 135; 517.8 |
Lung or lobar lung retransplantation after a failed lung or lobar lung transplant may be considered **medically necessary** in patients who meet criteria for lung transplantation.

**When Policy Topic is not covered**
Lung or lobar lung transplantation is considered investigational in all other situations.

**Considerations**
Lung and lobar lung transplants should be considered for coverage under the Transplant Benefit.

**General**
Potential contraindications subject to the judgment of the transplant center:
1. Known current malignancy, including metastatic cancer
2. Recent malignancy with high risk of recurrence
3. Untreated systemic infection making immunosuppression unsafe, including chronic infection
4. Other irreversible end-stage disease not attributed to lung disease
5. History of cancer with a moderate risk of recurrence
6. Systemic disease that could be exacerbated by immunosuppression
7. Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

**Policy-specific**
8. Coronary artery disease (CAD) not amenable to percutaneous intervention or bypass grafting, or associated with significant impairment of left ventricular function*; or
9. Colonization with highly resistant or highly virulent bacteria, fungi, or mycobacteria.

*Some patients may be candidates for combined heart-lung transplantation.
Patients must meet UNOS guidelines for lung allocation score (LAS) greater than zero.

**Lung Specific**
Bilateral lung transplantation is typically required when chronic lung infection disease is present, i.e., associated with cystic fibrosis and bronchiectasis. Some, but not all, cases of pulmonary hypertension will require bilateral lung transplantation.

Bronchiolitis obliterans is associated with chronic lung transplant rejection, and thus may be the etiology of a request for lung retransplantation.
Transplant Benefit
Lung transplants should be considered for coverage under the Transplant benefit.

Items covered under the scope of the Human Organ Transplant (HOT) benefit need to be considered.

Typically, the following are covered under the HOT benefit:
- hospitalization of the recipient for medically recognized transplants from a donor to a transplant recipient;
- evaluation tests requiring hospitalization to determine the suitability of both potential and actual donors, when such tests cannot be safely and effectively performed on an outpatient basis;
- hospital room, board, and general nursing in semiprivate rooms;
- special care units, such as coronary and intensive care;
- hospital ancillary services;
- physicians’ services for surgery, technical assistance, administration of anesthetics, and medical care;
- acquisition, preparation, transportation, and storage of organ;
- diagnostic services;
- drugs that require a prescription by federal law.

Expenses incurred in the evaluation and procurement of organs and tissues are benefits when billed by the hospital. Included in these expenses may be specific charges for participation with registries for organ procurement, operating rooms, supplies, use of hospital equipment, and transportation of the tissue or organ to be evaluated.

Administration of products with a specific transplant benefit needs to be defined as to:
- when the benefit begins (at the time of admission for the transplant or once the patient is determined eligible for a transplant, which may include tests or office visits prior to transplant);
- when the benefit ends (at the time of discharge from the hospital or at the end of required followup, including the immunosuppressive drugs administered on an outpatient basis).

Coverage usually is not provided for:
- HOT services for which the cost is covered/funded by governmental, foundational, or charitable grants;
- organs sold rather than donated to the recipient;
- an artificial organ.

Description of Procedure or Service
A lung transplant consists of replacing all or part of diseased lungs with healthy lung(s). Transplantation is an option for patients with end-stage lung disease.
The literature on lung and lobar lung transplantation, which consists of case series and registry data, demonstrates that lung and lobar lung transplantation provides a survival benefit in appropriately selected patients and thus may be considered medically necessary. It may be the only option for some patients with end-stage lung disease.

The literature on lung retransplantation is limited but is accumulating in registry data. As in lung transplantation, lung retransplantation may be the only option for patients with failed lung transplantation.

Background
End-stage lung disease may be the consequence of a number of different etiologies. The most common indications for lung transplantation are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), alpha-1 antitrypsin deficiency, and idiopathic pulmonary arterial hypertension (IPAH). Prior to the consideration for transplant, patients should be receiving maximal medical therapy, including oxygen supplementation, or surgical options, such as lung-volume reduction surgery for COPD. Lung or lobar lung transplantation is an option for patients with end-stage lung disease despite these measures.

A lung transplant refers to single-lung or double-lung replacement. In a single-lung transplant, only one lung from a deceased donor is provided to the recipient. In a double-lung transplant, both the recipient's lungs are removed and replaced by the donor's lungs. In a lobar transplant, a lobe of the donor’s lung is excised, sized appropriately for the recipient’s thoracic dimensions, and transplanted. Donors for lobar transplant have primarily been living-related donors, with one lobe obtained from each of two donors (e.g., mother and father) in cases for which bilateral transplantation is required. There are also cases of cadaver lobe transplants. Combined lung-pancreatic islet cell transplant is being studied for patients with cystic fibrosis. (1)

Since 2005, potential recipients have been ranked according to the Lung Allocation Score (LAS). (2) Patients 12 years of age and older receive a score between 1 and 100 based on predicted survival after transplantation reduced by predicted survival on the waiting list; the LAS takes into consideration the patient’s disease and clinical parameters. In 2010, a simple priority system was implemented for children under the age of 12. Under this system, children under 12 with respiratory lung failure and/or pulmonary hypertension who meet criteria are considered “priority 1” and all other candidates in the age group are considered “priority 2”. A lung review board (LRB) has authority to adjust scores on appeal for adults and children.

Rationale

This policy was originally created in 1996 and updated regularly with searches of the MEDLINE database. The most recent literature search was performed for the
period of December 22, 2013, through December 18, 2014. Due to the nature of the population, there are no randomized controlled trials (RCTs) that compare lung transplantation with alternatives. Systematic reviews are based on case series and registry data. The extant RCTs compare surgical technique, infection prophylaxis, or immunosuppressive therapy and are not germane to this policy. The following is a summary of the evidence based on registries, case series, and expert opinion.

**Survival**
The Registry of the International Society for Heart and Lung Transplantation (ISHLT) contains data from 42,069 adult recipients who received lung transplantation (including lung retransplantation) before 2012.(4) Reports from 132 transplant centers around the world were obtained on 3640 lung transplants performed in 2011. The overall median survival of patients who underwent lung transplantation between June 1994 and June 2011 was 5.6 years. In the first 30 days after transplantation, the major reported causes of mortality were graft failure and noncytomegalovirus (non-CMV) infections while non-CMV infections became the major cause of death for the remainder of the first year. Beyond the first year, the most common reported causes of mortality were bronchiolitis obliterans, graft failure (lung rejection or bronchiolitis obliterans) and non-CMV infections. Over time, the proportion of patients who died from malignancies increased; malignancies accounted for 15% of all deaths between 5 and 10 years after transplant. Authors of a 2009 review of the current status of lung transplantation observed that while transplantation can prolong survival, survival statistics for lung transplantation are not as favorable as in patients receiving other solid organ transplants.(5)

In 2014, Kistler et al reported on a systematic review of the literature on waitlist and posttransplant survival of idiopathic pulmonary fibrosis.(6) Estimated median survival of idiopathic pulmonary fibrosis patients posttransplantation is estimated at 4.5 years and is lower than other underlying pretransplant diagnoses. From ISHLT and the Organ Procurement and Transplantation Network (OPTN) data, 1-year survival ranged from 75% to 81%; 3-year, 59% to 64%, and 5-year, 47% to 53%. Limited data were available on posttransplant morbidity outcomes.

In 2009, Thabut et al reported on a comparison of patients undergoing single- and double-lung transplantation for idiopathic pulmonary fibrosis.(7) A retrospective review was conducted of 3327 patients with data in the United Network for Organ Sharing (UNOS) registry. More patients underwent single-lung compared with double-lung transplant (64.5% vs 35.5%, respectively). Median survival time was greater for the double-lung group at 5.2 years (95% confidence interval [CI], 4.3 to 6.7 years) versus 3.8 years (95% CI, 3.6 to 4.1 years; p<0.001). After adjustment for baseline differences, however, survival times were not statistically different. The authors concluded that overall survival did not differ between the 2 groups: single-lung transplants offered improved short-term survival but long-term harm, whereas doublelung transplant increased short-term harm but was associated with a long-term survival benefit. In 2014, Black et al reported on LAS and single versus double lung transplant in 8778 patients (8050 had an LAS <75 and 728 had an LAS ≥75).(8) A significant decrease in survival was seen in single-
lung transplant patients with a high LAS compared with double-lung transplant patients with a high LAS, even though operative morbidity was higher ($p<0.001$).

**Patient Selection**

In 2008, Kozower et al performed a retrospective cohort study using data from 5 academic medical centers to evaluate the impact of a new lung allocation score on short-term outcomes after lung transplantation.(9) (This lung allocation score was implemented in May 2005 by OPTN.) This new score changed lung allocation from a system based on waiting time to an algorithm based on the probability of survival for 1 year on the transplant list and survival 1-year posttransplantation. Results were compared for 170 patients who received transplants on the basis of the new lung allocation scores (May 4, 2005-May 3, 2006) with those of 171 patients who underwent transplants the preceding year before implementation of the scoring system. Waiting time decreased from 681 to 445.6 days ($p<0.001$). Recipient diagnoses changed, with an increase (15% to 25%) in idiopathic pulmonary fibrosis cases and decreases in emphysema (46% to 34%) and cystic fibrosis (23% to 13%). Hospital mortality and 1-year survival were the same between groups (5.3% vs 5.3% and 90% vs 89%, respectively). Presumably due to increased severity of illness, the incidence of primary graft dysfunction and postoperative intensive care unit length of stay increased in the year after implementation of the scoring system; graft dysfunction grew from 14.8% (24/170) to 22.9% (39/171); ($p=0.04$) and length of stay rose from 5.7 to 7.8 days.

In 2010, Yusen et al reviewed the effect of the LAS on lung transplantation by comparing statistics for the period before and after its implementation in 2005.(10) Other independent changes in clinical practice, which may affect outcomes over the same period of time, include variation in immunosuppressive regimens, an increased supply of donor lungs, changes in diagnostic mix, and increased consideration of older recipients. Deaths on the waiting list declined following implementation of the LAS system, from approximately 500 per 5000 patients to 300 per 5000 patients. However, it is expected that implementation of LAS affected patient characteristics of transplant applicants. One-year survival posttransplantation did not improve after implementation of the LAS system: patient survival data before and after are approximately 83%. Long-term survival data are not yet available for comparison. In 2014, Shafii et al reported on a retrospective evaluation of the LAS and mortality in 537 adults listed for lung transplantation and 426 who underwent primary lung transplantation between 2005 and 2010.(11) Patients on the waitlist who had a higher LAS had a higher rate of mortality ($p<0.001$). In the highest quartile of LAS, ranging from 47 to 95, within 1 year of listing, there was a 75% mortality rate. Higher LAS was also associated with early posttransplant survival ($p=0.05$) but not late posttransplant survival ($p=0.4$). When other predictive factors of early mortality were accounted for, pretransplant LAS was not independently related to posttransplant mortality ($p=0.12$).

**Pediatric Considerations**
In 2012, Benden et al reviewed pediatric lung transplants that have been reported to the international registry. Pediatric patients are defined as those younger than 18 years of age. The authors noted an increase in the number of pediatric lung transplants in recent years; there were 126 transplants in 2010 compared with 73 in 2000. In contrast to adult patients, the most common indication for pediatric patients was cystic fibrosis, accounting for 54% of lung transplants in 6- to 11-year-olds and 72% of lung transplants in 12- to 17-year-olds that occurred between 1990 and June 2011. Survival has improved in the recent era, and 5-year survival is not significantly different from adult recipients. The half-life, estimated time at which 50% of recipients have died, was 4.7 years for children and 5.3 years for adults. For children receiving allografts between 2002 and June 2010, the 5-year survival rate was 54% and 7-year survival was 44%. Patients aged 1 to 11 years had a significantly better survival rate than those between the ages of 12 and 17 years (half-life of 6.2 years and 4.3 years, respectively). In the first year after lung transplantation, non-CMV infection and graft failure were the 2 leading causes of death. Bronchiolitis obliterans syndrome was the major cause of death beyond 3 years after transplantation.

**Potential Contraindications**

**Malignancy**
Malignancies are common after lung transplantation with 21% and 40% of patients reporting 1 or more malignancies at 5 and 10 years posttransplantation, respectively. Skin cancer occurred most frequently and lymphoproliferative disorders were the malignancies most associated with morbidity posttransplantation.

A 2012 study reported on outcomes in patients with lung cancer who were lung transplant recipients. Ahmad et al identified 29 individuals in the UNOS database who underwent lung transplantation for advanced bronchoalveolar carcinoma (BAC). These patients represented 0.13% of the 21,553 lung transplantations during the study period. BAC and general lung transplant recipients had similar survival rates: the 30-day mortality rate was 7% versus 10% (p=0.44) and 5-year survival rate was 50% versus 57% (p=0.66).

**HIV**
Solid organ transplant for patients who are HIV-positive has been controversial, due to the long-term prognosis for HIV positivity and the impact of immunosuppression on HIV disease. Although HIV-positive transplant recipients may be of research interest at some transplant centers, the minimal data regarding long-term outcome in these patients primarily consist of case reports and abstract presentations of liver and kidney recipients. Nevertheless, some transplant surgeons would argue that HIV positivity is no longer an absolute contraindication to transplant due to the advent of highly active antiretroviral therapy (HAART), which has markedly changed the natural history of the disease.
As of October 2013, the OPTN policy on HIV status in recipients states: “A potential candidate for organ transplantation whose test for HIV is positive should not be excluded from candidacy for organ transplantation unless there is a documented contraindication to transplantation based on local policy.”

In 2006, the British HIV Association and the British Transplantation Society Standards Committee published guidelines for kidney transplantation in patients with HIV disease.(15) These criteria may be extrapolated to other organs:

- CD4 count greater than 200 cells/mL for at least 6 months
- Undetectable HIV viremia (<50 HIV-1 RNA copies/mL) for at least 6 months
- Demonstrable adherence and a stable HAART regimen for at least 6 months
- Absence of AIDS-defining illness following successful immune reconstitution after HAART.

**Other Infections**

Infection with *Burkholderia cenocepacia* is associated with increased mortality in some transplant centers, a factor that may be taken into account when evaluating overall risk for transplant survival.(16) Two articles published in 2008 evaluated the impact of infection with various species of *Burkholderia* on outcomes for lung transplantation for cystic fibrosis. In a study published by Murray et al, multivariate Cox survival models assessing hazard ratios (HRs) were applied to 1026 lung transplant candidates and 528 transplant recipients.(17) Of the transplant recipients, 88 were infected with *Burkholderia*. Among transplant recipients infected with *B cenocepacia*, only those infected with nonepidemic strains (n=11) had significantly greater posttransplant mortality than uninfected patients (HR=2.52; 95% CI, 1.04 to 6.12; p=0.04). Transplant recipients infected with *Burkholderia gladioli* (n=14) also had significantly greater posttransplant mortality than uninfected patients (HR=2.23; 95% CI, 1.05 to 4.74; p=0.04). When adjustments for specific species/strains were included, lung allocation scores of *Burkholderia multivorans* infected transplant candidates were comparable with uninfected candidate scores, and scores for patients infected with nonepidemic *B cenocepacia* or *B gladioli* were lower. In a smaller study of 22 patients colonized with *Burkholderia cepacia* complex who underwent lung transplantation in 2 French centers, the risk of death by univariate analysis was significantly higher for the 8 patients infected with *B cenocepacia* than for the other 14 colonized patients (11 of whom had *B multivorans*).(18)

In 2012, Shields et al reported on infections in 596 consecutive lung transplant recipients treated at a single center occurring in the first 90 days after transplantation.(19) A total of 109 patients (18%) developed 138 *Staphylococcus aureus* infections. The most common type of infection was pneumonia (66 of 138, 48%) followed by tracheobronchitis (36/138 [26%]) and bacteremia (17/138 [12%]). Thirteen of 109 (12%) patients with *S aureus* infection died within 90 days of the onset of infection. The 1-year mortality rate was higher for patients with *S aureus* pneumonia (19/ 66 [29%]) but not *S aureus* tracheobronchitis (8/36 [22%]) compared with uninfected patients (85/487 [17%]).
Pinney et al published a retrospective review of invasive fungal infection rates in lung transplantation patients without cystic fibrosis treated at a single center.\textsuperscript{(20)} Patients were followed for a median of 34 months. Invasive fungal infections were identified in 22 of 242 (9.1\%) patients. \textit{Aspergillus} infections were most common, occurring in 11 of 242 (4.5\%) of patients. There were also 7 cases (3\%) of \textit{Candida} infection. Survival rates did not differ significantly in patients with invasive fungal infections compared with the entire cohort of patients. For example, 3-year survival was 50\% among patients with invasive fungal infection and 66\% in the entire cohort (p=0.66). The authors did not compare survival in patients with invasive fungal infections with survival only in those without invasive fungal infections.

In 2013, Lobo et al reported on 13 lung transplant patients with \textit{Mycobacterium abscessus} in cystic fibrosis.\textsuperscript{(21)} Survival rates were 77\%, 64\%, and 50\% after transplant at 1, 3, and 5 years, respectively. These results were not significantly different when compared with 154 cystic fibrosis patients treated with lung transplantation who did not have \textit{M abscessus} (p=0.8).

**Coronary Artery Disease**

Castleberry et al reported on a retrospective cohort study of lung transplantation with concurrent coronary bypass (CAB) or preoperative percutaneous coronary intervention (PCI).\textsuperscript{(22)} Of 898 lung transplants performed during the period between 1997 and 2010, 49 patients also had concurrent CAB and 38 patients had preoperative PCI. All of the intervention groups, including revascularization, had similar rates of perioperative mortality, overall unadjusted survival, and adjusted hazard ratio for cumulative risk of death. Postoperative major adverse cardiac event rates were also similar among groups, although postoperative length of stay, intensive care unit time and need for ventilator support increased in patients receiving concurrent CAB with lung transplantation.

In 2011, Sherman et al reported on outcomes in 27 patients with coronary artery disease (CAD) at a single center who underwent lung transplantation and coronary revascularization.\textsuperscript{(23)} Patients needed to be otherwise considered good candidates for transplantation and have discrete coronary lesions (at least 50\% in the left main artery or at least 70\% in other major vessels) and preserved ejection fraction. Thirteen patients had single-lung transplantation and 14 had double-lung transplantation. Outcomes were compared with a control group of 81 patients without CAD who underwent lung transplantation; patients were matched for age, diagnosis, lung allocation score and type of procedure. During a mean follow-up of 3 years, 9 of 27 (33\%) patients with CAD and 28 of 81 (35\%) without CAD died (p=0.91). Bronchiolitis obliterans and infection were the primary causes of death. There was no significant difference between groups in a composite outcome of adverse cardiac events (defined as acute coronary syndrome, redo revascularization, or hospital admissions for heart failure) (p=0.80).

**Lobar Lung Transplantation**
Several case series have reported outcomes after lobar lung transplants in both children and adults. In 2005, Barr et al reported on experience performing living donor lobar lung transplants in the United States.(24) Ninety patients were adults and 43 were children. The primary indication for transplantation (86%) was cystic fibrosis. At the time of transplantation, 67% of patients were hospitalized and 20% were ventilator dependent. Overall recipient actuarial survival at 1, 3, and 5 years was 70%, 54%, and 45%, respectively. There was not a statistically significant difference in actuarial survival between adults and children who underwent transplantation. Moreover, survival rates were similar to the general population of lung transplant recipients. The authors also reported that rates of postoperative pulmonary function in patients surviving more than 3 months posttransplant were comparable with rates in cadaveric lung transplant recipients.

In 2014 Date et al reported on a retrospective study comparing 42 living-donor lobar lung transplants and 37 cadaveric lung transplants.(25) Survival rates at 1 and 3 years were not significantly different between the groups (89.7 and 86.1% vs 88.3 and 83.1%, respectively, p=0.55), despite living-donor lobar lung transplant patients having poorer health status preoperatively. In 2012, a program in Japan reported on 14 critically ill patients who had undergone single living-donor lobar lung transplants; there were 10 children and 4 adults.(26) Patients were followed for a mean 45 months. The 3-year survival rate was 70% and the 5-year survival was 56%. Severe graft dysfunction occurred in 4 patients. Mean forced vital capacity (FVC) was found to be lower in patients experiencing severe graft dysfunction compared with the other patients, mean FVC was 54.5% and 66.5%, respectively. The authors stated that this suggests size mismatching in the patients with severe graft dysfunction. Also in 2012, Inci et al published data on 23 patients in Switzerland who received bilateral lobar lung transplants.(27) The mean age was 41 years (range, 13-66). Survival at 1 and 2 years was 82% and 64%, respectively; survival rates were comparable with 219 patients who underwent bilateral lung transplantation during the same time period (p=0.56).

A review article by Date stated that, as of 2011, approximately 400 living-donor lobar lung transplants have been performed worldwide.(28) Procedures in the United States decreased after 2005 due to changes in the lung allocation system. The author stated that size matching between donor and recipient is important and that, to some extent, size mismatching (oversized or undersized grafts) can be overcome by adjusting surgical technique.

In 2014 Slama et al reported on a comparison of outcomes in 138 cadaveric lobar lung transplants (for size discrepancies) to 778 patients who received cadaveric whole-lung transplants, 239 of whom had downsizing by wedge resection of the right middle lobe and/or the left lingula.(29) Survival in the lobar lung transplant group at 1 and 5 years was 65.1% and 54.9% versus 84.8% and 65.1% in the whole lung and downsized by wedge resection group (p<0.001). The lobar lung transplantation group experienced significantly inferior early postoperative outcomes, but in patients who were successfully discharged, survival rates were similar to standard lung transplantation (p=0.168).
Retransplantation
Registry data and case series reports have demonstrated favorable outcomes with lung retransplantation in certain populations, such as in patients who meet criteria for initial lung transplantation.(4,30,31) The ISHLT Registry contains data on 970 retransplantation patients for the period of January 1995 to June 2012 (2.6% of all lung transplantations during this period). Lung retransplantation occurred most commonly for bronchiolitis obliterans syndrome in 568 patients, while 402 patients received retransplantation for other reasons.(4) In an analysis of lung transplantation during the period of January 1999 to June 2011, retransplantation was associated with an increased risk of death within 1 year after lung transplantation (HR=1.69; 95% CI, 1.38 to 2.07; p<0.001).(4) However, for patients surviving at least 1 year, the risk of death was no longer associated with retransplantation.

In 2013, Kilic et al evaluated data on 390 adult lung retransplantation patients from the UNOS database.(30) Patients received lung retransplantation during the period May 2005 to December 2010, which was after the LAS selection criteria were implemented. Patients with reduced functional status were found to have poorer outcomes than patients with better functional status before retransplantation. Using the Karnofsky scale to stratify patients into functional status groups, the authors found the overall 1-year survival of 56% for patients requiring total assistance before retransplantation was significantly lower than the overall 1-year survival of 82% for patients who only required some assistance before retransplantation (p<0.001). The 1-year mortality rate after risk adjustment was also increased significantly for patients requiring total assistance before retransplantation (odds ratio, 3.72; p=0.02). While additional patient selection criteria may be useful for lung retransplantation, current LAS criteria are now used.

Summary of Evidence
The literature on lung and lobar lung transplantation, which consists of case series and registry data, demonstrates that lung and lobar lung transplantation provides a survival benefit in appropriately selected patients and thus may be considered medically necessary. It may be the only option for some patients with end-stage lung disease.

The literature on lung retransplantation is limited but is accumulating in registry data. As in lung transplantation, lung retransplantation may be the only option for patients with failed lung transplantation.

Practice Guidelines and Position Statements
In 2006, the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation published consensus-based guidelines on selection of lung transplant candidates.(32) The guidelines state that:

“Lung transplantation is now a generally accepted therapy for the management of a wide range of severe lung disorders, with evidence supporting quality of life and survival benefit for lung transplant recipients.”
However, the number of donor organs available remains far fewer than the number of patients with end-stage lung disease who might potentially benefit from the procedure. It is of primary importance, therefore, to optimize the use of this resource, such that the selection of patients who receive a transplant represents those with realistic prospects of favorable long-term outcomes. There is a clear ethical responsibility to respect these altruistic gifts from all donor families and to balance the medical resource requirement of 1 potential recipient against those of others in their society. These concepts apply equally to listing a candidate with the intention to transplant and potentially delisting (perhaps only temporarily) a candidate whose health condition changes such that a successful outcome is no longer predicted.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
Lung transplantation is covered under Medicare when performed in a facility that is approved by Medicare as meeting institutional coverage criteria.(33) The Centers for Medicare and Medicaid Services have stated that under certain limited cases, exceptions to the facility-related criteria may be warranted if there is justification and the facility ensures safety and efficacy objectives.

References
32850  Donor pneumonectomy(s) (including cold preservation), from cadaver donor
32851  Lung transplant, single; without cardiopulmonary bypass
32852  Lung transplant, single; with cardiopulmonary bypass
32853  Lung transplant, double (bilateral sequential or en bloc); without cardiopulmonary bypass
32854  Lung transplant, double (bilateral sequential or en bloc); with cardiopulmonary bypass
32855  Backbench standard preparation of cadaver donor lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare pulmonary venous/atrial cuff, pulmonary artery, and bronchus; unilateral
32856  Backbench standard preparation of cadaver donor lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare pulmonary venous/atrial cuff, pulmonary artery, and bronchus; bilateral
S2060  Lobar lung transplantation
S2061  Donor lobectomy (lung) for transplantation, living donor

ICD-10 Codes

A15.0  Tuberculosis of lung (includes tuberculous fibrosis of lung)
C96.6  Unifocal Langerhans-cell histiocytosis (includes eosinophilic granuloma of lung)
D48.1  Neoplasm of uncertain behavior of connective and other soft tissue (includes lymphangiomyomatosis)
D86.0; D86.2  Sarcoidosis of lung and sarcoidosis of lung with sarcoidosis of lymph nodes, respectively
E84.0-  Cystic fibrosis code range
E84.9
E88.01  Alpha-1-antitrypsin deficiency
I26.01- I26.99  Pulmonary embolism, acute code range
I27.0  Primary pulmonary hypertension
I27.2  Other secondary pulmonary hypertension (includes pulmonary hypertension due to cardiac disease)
I27.82  Chronic pulmonary embolism
I27.89  Other specified pulmonary heart diseases (includes Eisenmenger's syndrome)
J42  Unspecified chronic bronchitis (includes bronchiolitis obliterans)
J43.0-  Emphysema code range
J43.9
J44.9  Chronic obstructive pulmonary disease, unspecified
J47.0-  Bronchiectasis, acute codes
J47.1
J60-  Lung diseases due to external agents code range (includes pneumoconiosis and pulmonary fibrosis due to fumes and vapors)
J70.9
J84.1  Other interstitial pulmonary diseases with fibrosis
M34.0-  Systemic sclerosis [scleroderma] (especially M34.81 – Systemic
M34.9  Sclerosis with lung involvement
P27.0-  Chronic respiratory disease originating in the perinatal period (includes bronchopulmonary dysplasia)
P27.9  Congenital malformations of lung code range (includes congenital bronchiectasis)
Q33.0-  Congenital malformations of lung code range (includes congenital bronchiectasis)
Q33.9  Bronchiectasis

Additional Policy Key Words
N/A

Policy Implementation/Update Information
11/1/01  New policy. Added to the Surgery / Transplant sections.
11/1/02  No policy statement changes.
11/1/03  Policy statement revised to remove pulmonary fibrosis as a covered indications. New codes added.
11/1/04  No policy statement changes.
11/1/05  No policy statement changes.
4/1/06  Added general criteria to the considerations section.
11/1/06  No policy statement changes.
11/1/07  No policy statement changes.
11/1/08  No policy statement changes.
11/1/09  No policy statement changes.
11/1/10  No policy statement changes.
11/1/11  Policy statement and Considerations reorganized by moving detail from Considerations to policy statements.
11/1/12  Absolute contraindications moved to Policy Guidelines and combined with relative complications; wording consistent with other transplant policies.
11/1/13  In lobar lung statement, “children and adolescents” replaced with “carefully selected patients” and coding correction: lymphangiomyomatosis corrected to 516.4
11/1/14  Policy statement added indicating lung or lobar lung retransplantation may be medically necessary. Policy statement added that lung or lobar lung transplantation is considered investigational in all other situations (previously considered not medically necessary)
11/1/15  No policy statement changes.
11/1/16  No policy statement changes.

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.